Founded in 1990, Zhejiang Jingxin Pharmaceutical Co., Ltd. is a listed pharmaceutical company integrating R&D, production and sales. Adhering to the business guideline of “strengthening the main business of pharmaceuticals and developing medical devices”, we adhere to the core values of “pragmatic, innovative, inclusive and win-win”. Jingxin aims to fulfill our duty of “careful protection of health” and to take the lead in psycho-neural and cardiovascular fields.
Up to now, the company has a registered capital of 706 million yuan, total assets of 5.6 billion yuan and net assets of 3.6 billion yuan. The company has more than 3,300 employees, including more than 210 doctors and masters.The company has two headquarters in Xinchang and Hangzhou. It has six production sites including the plant in Xinchang for finished medicines, the two API plants in Shangyu and Shangrao, the TCM production site in Bayannaoer, Inner Mongolia, and the medical equipment production base of Shenzhen and Shenyang. Aside from that, the company also owns a breeding base in Yunnan. In Shanghai, the company has established its own research institute i n the Zhangjiang Hi-Tech Park. Joint ventures and collaberated labs have also been founded over the years in the U.S.A., Denmark, Isereal, Korea as well as other countries.
All along, the company has been adhering to the "Jingxin drug, meticulously made" quality concept. It has passed the new version of GMP certification, the solid preparation production line took the lead in 2006 by passing the German GMP certification. In 2018, it also passed the FDA on-site certification. The company's comprehensive economics have been rapidly improved. It was listed as one of the "Top 100 Chinese Pharmaceutical Industry Brands", "Top 100 Chinese Pharmaceutical Industry" and "Top 100 Chinese Chemical Pharmaceutical Enterprises" for many years. It was recognized as the first batch of " Leading Chinese pharmaceutical companies in the internationalization of preparations", gainging increasing the social popularity and reputation.
The company is a national key high-tech enterprise, with a national enterprise technology center, post-doctoral research station, provincial key enterprise research institute, provincial academician expert workstation, provincial high-tech enterprise R & D center, and Shanghai Research Institute in Shanghai Zhangjiang Hi-Tech Park. It enjoys long-term good communication and cooperation with Shanghai Institute of Pharmaceutical Industry, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Zhejiang University and other famous domestic and foreign research institutes, research and development companies, and famous universities. The company is strong in research and technology with fruitful results in R&D. It now has 8 national key new products and is in charge of 9 national Torch Program projects.
Up to 2020, Jingxin has 179 effective patents, including 106 domestic invention patents, 4 US invention patents, reflecting the company's strong research and development capabilities and innovation capabilities.More
Top 100 pharmaceutical companies in China
China Patent Gold Award
Zhejiang Province Science and Technology Progress First Prize
The first batch of innovative leading enterprises in Zhejiang Province
Top 100 fastest growing enterprises in Zhejiang Province
National key high-tech enterprises
National Enterprise Technology Center
Postdoctoral research station
Provincial Key Enterprise Research Institute
Provincial Academician Expert Workstation
Provincial High-tech Enterprise R&D Center
Passed the fifth certification of German (EU) GMP
Passed the US FDA CGMP on-site inspection
The first batch of "China Pharmaceutical Enterprise Preparation Internationalization Pioneer Enterprise"
Top Ten Leading Brands of Chinese Medicine
2018 National Intellectual Property Advantage Enterprise
First prize of science and technology progress of Yunnan Province
20 mg of simvastatin tablets and 0.25 g of cefuroxime axetil tablets have been evaluated by consistency.
The instrument product “stream” show for the first time in China，leading to a new era of neural intervention.
Rosuvastatin calcium tablets (specification 10mg) approved by the State Drug Administration for the issuance of drug registration approval.
5 mg and 10 mg of rosuvastatin calcium tablets and 5 mg of amlodipine besylate tablets have been evaluated by consistency. Among them, 0.25 g of levetiracetam tablets and 50 mg of sertraline hydrochloride tablets are the first to pass the quality and efficacy consistency of generic drugs. Evaluation;
“The research and industrialization of key technologies of statin series lipid-lowering drugs” won the first prize of 2017 Zhejiang Science and Technology Progress Award issued by Zhejiang Provincial People's Government.
The rivastigmine valsartan capsule (specification 1.5mg and 3.0mg), pramipexole hydrochloride tablets (size 0.25mg and 1.0mg) approved by the State Food and Drug Administration for the issuance of drug registration approval.
Solid preparation line passed FDA on-site certification.
The new office building of Jingxin Pharmaceutical Research Institute was officially opened.
Invest in the development of Israeli P2B pharmaceutical preparations.
Invest in Israel's Perflow innovative plugging interventional device.
Invest in the US SPES R&D platform construction project.
The company's technology center was included in the list of the 22nd batch of nationally recognized enterprise technology centers.
Tnvest in MAPI's long-term and safe neuropsychotic preparation technology research and development.
The successful acquisition of Shenzhen Juyi Display Technology Co., Ltd. marks the company's substantial progress in the field of medical devices.
For the first time, we will take the pace of overseas expansion and establish a British joint venture company (SEPS).
The company's sertraline hydrochloride and its preparation projects were included in the National Torch Program Industrialization Demonstration Project.
Levetiracetam and tablets obtained the production approval issued by the State Food and Drug Administration.
The company's first biological product, Bacillus licheniformis live capsule, passed the provincial new product appraisal and was recognized as the international leader in technology.
The company's first class 1.1 innovative drug EVT201 obtained the drug clinical trial approval issued by the State Food and Drug Administration.
"Jing Changle" successfully listed
Acquired Beijing Shunda Sihai Biomedical Co., Ltd. and officially entered the field of biomedicine
Invested in the target assets of Linhe Chinese Medicine Factory in Bayannaoer, Hetao Plain, and established Inner Mongolia Jingxin Pharmaceutical Co., Ltd.
Listed on the Shenzhen Stock Exchange (stock code: 002020)
Established Zhejiang Jingxin Pharmaceutical Co., Ltd.
Established Zhejiang Jingxin Pharmaceutical Factory
Jingxin Pharmaceutical has a mission of meticulously guarding health, respecting life and creating value. With the core values of “pragmatic innovation, inclusiveness and win-win”, the road has not changed. Jingxin people pursue excellence, diligence and tirelessness, stand in the United States, and have a broad world. With the extraordinary wisdom and vision of Jingxin people, they are dedicated to the society.
Quality commitment, quality first. We have established quality monitoring institutions to build a scientific and perfect control system to enhance the comprehensive testing and control capabilities of various medical products.
Innovation and technology, change management. We open the door of technology with innovative thinking, and explore the high-tech fields such as surgical navigation, long-acting injection, and medical equipment with the world's top experts, and strive to shine the glory of Chinese pharmaceutical companies on the stage of global competition.
I will use it well and be good at it. Focusing on the overall strategy of the company, we have vigorously promoted the talent double-eagle plan, and built a dream stage for all kinds of talents to build a talented team that adapts to the company's rapid development.
Ingenuity is forever, but the only one. We introduce international leading production equipment, standardize process, improve supporting facilities, increase production capacity, and lay a solid foundation for Beijing New High-end quality!
Jingxin Pharmaceutical adheres to the business philosophy of “strengthening the main business of pharmaceuticals and developing medical devices”. Based on the two headquarters of Xinchang Hangzhou, we adhere to the positive, healthy and steady development pace of the initial heart, pioneering and innovating, looking forward to the future, and persisting in meticulous care. The mission of guarding health is to realize the beautiful vision of Beijing New Earth.
Jingxin Pharmaceutical adheres to the mission of meticulously guarding health and is committed to becoming a leader in the field of Chinese mental and cardiovascular diseases.